Performance of a cell‐free DNA prenatal screening test, choice of prenatal procedure, and chromosome conditions identified during pregnancy after low‐risk cell‐free DNA screening
Prenatal Diagnosis · 2023-02 · 43 (2) · 213-225
DOI: 10.1002/pd.6307 ↗Kurz gefasst
Fachartikel in der Zeitschrift Prenatal Diagnosis, online erschienen am 21.01.2023. Verfasst von Katrina L Scarff und 8 weiteren Autor:innen. Beteiligte Einrichtung: Victorian Clinical Genetics Services, Murdoch Children's Research Institute, Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: Cell-Free Nucleic Acids, Chromosome Disorders. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Objectives
To evaluate the performance of cell‐free DNA (cfDNA) screening for common fetal aneuploidies, choice of prenatal procedure, and chromosome conditions identified during pregnancy after low‐risk cfDNA screening.
Method
A single‐center prenatal cfDNA screening test was employed to detect trisomies 21, 18, and 13 (T21, T18, T13) and sex chromosome aneuploidies (SCAs). Test performance, choice of prenatal procedure, and cytogenetic results in pregnancies with low‐risk cfDNA screening were reviewed.
Results
CfDNA screening of 38,289 consecutive samples identified 720 (1.9%) pregnancies at increased risk for aneuploidy. Positive predictive values (PPVs) for high‐risk singleton pregnancies were 98.5% (T21), 92.5% (T18) and 55.2% (T13). PPVs for SCAs ranged from 30.6% to 95.2%. Most women elected chorionic villus sampling for prenatal diagnosis of T21, T18 and T13; amniocentesis and/or postnatal testing were commonly chosen for SCAs. Cytogenetic tests from 616 screen‐negative pregnancies identified 64 cases (12.7%) with chromosome conditions not detected by cfDNA screening, including triploidy ( n = 30) and pathogenic and likely pathogenic copy number variants ( n = 34). A further 15 (0.04%) false‐negative common aneuploidy results were identified.
Conclusions
CfDNA screening was highly accurate for detecting fetal aneuploidy in this general‐risk obstetric population. Fetal ultrasound and prenatal diagnostic testing were important in identifying chromosome conditions in pregnancies screened as low‐risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Victorian Clinical Genetics Services, Murdoch Children's Research Institute, Parkville, Victoria, Australia.
- Department of Paediatrics, University of Melbourne, Parkville, Victoria, Australia.
- Bruce Lefroy Centre, Murdoch Children's Research Institute, Parkville, Victoria, Australia.
ORCID-Profile: Katrina L Scarff, Mark D Pertile
Zitieren
APA
Scarff, K. L., Flowers, N., Love, C. J., Archibald, A. D., Hunt, C. E., Giouzeppos, O., Elliott, J., Delatycki, M. B., & Pertile, M. D. (2023). Performance of a cell‐free DNA prenatal screening test, choice of prenatal procedure, and chromosome conditions identified during pregnancy after low‐risk cell‐free DNA screening. Prenatal Diagnosis, 43(2), 213-225. https://doi.org/10.1002/pd.6307
Vancouver
Scarff KL, Flowers N, Love CJ, Archibald AD, Hunt CE, Giouzeppos O, et al. Performance of a cell‐free DNA prenatal screening test, choice of prenatal procedure, and chromosome conditions identified during pregnancy after low‐risk cell‐free DNA screening. Prenatal Diagnosis. 2023;43(2):213-225. doi:10.1002/pd.6307
BibTeX
@article{Scarff2023,
author = {Scarff, Katrina L and Flowers, Nicola and Love, Clare J and Archibald, Alison D and Hunt, Clare E and Giouzeppos, Olivia and Elliott, Justine and Delatycki, Martin B and Pertile, Mark D},
title = {Performance of a cell‐free DNA prenatal screening test, choice of prenatal procedure, and chromosome conditions identified during pregnancy after low‐risk cell‐free DNA screening},
journal = {Prenatal Diagnosis},
year = {2023},
volume = {43},
number = {2},
pages = {213--225},
doi = {10.1002/pd.6307}
}
EUVIMED